Represented Titan Pharmaceuticals, Inc. in general corporate matters

Advised Titan Pharmaceuticals’ board of directors in connection with its dealings with an activist shareholder, including evaluation of strategic alternatives (including sales of intellectual property assets), financing opportunities, bylaw amendments, communications with public shareholders, expansion of the board of directors and the change in senior management.